Press Releases
June 22, 2022
In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 22, 2022-- Aura Biosciences Inc.
May 25, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 25, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will
May 3, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive
Displaying 1 - 10 of 15